Anti-Human ANGPTL3 (Evinacumab)

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Evinacumab. Evinacumab is designed to specifically target Angiopoietin-like protein 3 (ANGPTL3).

Angiopoietin-like protein 3 (ANGPTL3) is a glycoprotein primarily produced in the liver and plays a crucial role in lipid metabolism. It hinders the function of lipoprotein lipase (LPL) and endothelial lipase (EL) which are essential for breaking down triglycerides and phospholipids. By blocking these enzymes ANGPTL3 increases the levels of triglycerides LDL cholesterol and HDL cholesterol in the blood. Research has shown that mutations in ANGPTL3 that result in reduced function are associated with lower lipid levels and a reduced risk of coronary artery disease^1-3.

The monoclonal antibody REGN 1500, also known as evinacumab, targets ANGPTL3 to treat hypercholesterolemia (HoFH) a rare genetic condition characterized by extremely high cholesterol levels. Evinacumab works by inhibiting ANGPTL3, which helps break down fats and leads to a decrease in low-density lipoprotein cholesterol (LDL-C). Clinical trials have proven that evinacumab can reduce LDL-C levels by around 47% in patients, with HoFH^4-7.

ANGPTL3 is found primarily in the liver; however, it is also expressed in other tissues, such as adipose tissue and podocytes in the kidney.

ANGPTL8

1. Lang W, Frishman WH. Cardiol Rev. 2019;27(4):211-217.
2. Jiang S, Qiu GH, Zhu N, Hu ZY, Liao DF, Qin L. J Drug Target. 2019;27(8):876-884.
3. Lai M, Jiang X, Wang B, Cheng Y, Su X. Curr Mol Med. 2024;24(6):771-779.
4. Banerjee P, Chan KC, Tarabocchia M, et al. Arterioscler Thromb Vasc Biol. 2019;39(11):2248-2260.
5. Gao Y, Zhang B, Yang J. Expert Rev Clin Pharmacol. 2022;15(2):139-145.
6. Raal FJ, Rosenson RS, Reeskamp LF, et al. N Engl J Med. 2020;383(8):711-720.
7. Stefanutti C, Chan DC, Di Giacomo S, Morozzi C, Watts GF. Pharmaceuticals (Basel). 2022;15(11):1389.